IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

The U.S. Food and Drug Administration (FDA) approved Axonics (NASDAQ:AXNX) fourth-generation rechargeable sacral neuromodulation system (SNM). SNM is a therapy to treat urinary incontinence. The ...

Based in Irvine, device maker Axonics Inc. reported fourth-quarter revenue climbed 61% to $85.6 million to $86 million, topping the $78.1 million expected by analysts. “This quarter’s record revenue ...

Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...

Federal Circuit said patent board should reconsider Axonics arguments Second revival of Axonics challenges to Medtronic patents since July Sign up here. Medtronic sued Axonics in California federal ...

Aug 7 (Reuters) - Axonics AXNX.O convinced the U.S. Court of Appeals for the Federal Circuit on Monday to revive its challenge to the validity of two Medtronic MDT.N patents, as the rival medical ...